SCHEMBL519257

SCHEMBL519257

CC(=O)C(=NNc1ccccc1)C(C)=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.56
RAB9A P51151 4/20 0.56
SMN1; SMN2 Q16637 4/20 0.56
MAPK1 P28482 3/20 0.56
NPC1 O15118 3/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
GFER P55789 2/20 0.56
KDM4E B2RXH2 1/20 0.54
GAA P10253 7/20 0.51
HTT P42858 1/20 0.51
ALDH1A1 P00352 5/20 0.50
NAPRT Q6XQN6 1/20 0.48
HSD17B10 Q99714 1/20 0.48
KMT2A Q03164 4/20 0.48
MEN1 O00255 3/20 0.48
RECQL P46063 1/20 0.48
TDP1 Q9NUW8 1/20 0.46
CYP3A4 P08684 1/20 0.45
ALOX5 P09917 1/20 0.45
TSHR P16473 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7490754 0.92 MAPT (0.54) MAPTRAB9ASMN1; SMN2MAPK1NPC1
SCHEMBL7490755 0.92 MAPT (0.54) MAPTRAB9ASMN1; SMN2MAPK1NPC1
SCHEMBL7487469 0.89 MAPT (0.51) MAPTRAB9ASMN1; SMN2MAPK1NPC1
SCHEMBL7487475 0.89 MAPT (0.51) MAPTRAB9ASMN1; SMN2MAPK1NPC1
SCHEMBL7487444 0.87 GFER (0.69) MAPTRAB9ASMN1; SMN2MAPK1NPC1
SCHEMBL7487450 0.87 GFER (0.69) MAPTRAB9ASMN1; SMN2MAPK1NPC1
SCHEMBL7482156 0.86 MAPT (0.49) MAPTRAB9ASMN1; SMN2MAPK1NPC1
SCHEMBL7482142 0.86 MAPT (0.49) MAPTRAB9ASMN1; SMN2MAPK1NPC1
SCHEMBL15440479 0.86 MAPT (0.50) MAPTRAB9ASMN1; SMN2MAPK1NPC1
SCHEMBL922004 0.83 GFER (0.49) MAPTRAB9ASMN1; SMN2MAPK1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12497368-B2 Arylazo-heteroaryl compounds and their use for long-term thermal energy storage BRANDEIS UNIVERSITY (US) 2025-12-16 US disclosed
CN-116368224-A ACE2 muteins and methods of use thereof 壹鸣生物公司 2023-06-30 CN disclosed
EP-4168541-A2 ACE2 MUTEINS AND METHODS OF USING THE SAME Emmune, Inc. (US) 2023-04-26 EP disclosed
US-20230053197-A1 ARYLAZO-HETEROARYL COMPOUNDS AND THEIR USE FOR LONG-TERM THERMAL ENERGY STORAGE IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2023-02-16 US disclosed
WO-2021158638-A1 ARYLAZO-HETEROARYL COMPOUNDS AND THEIR USE FOR LONG-TERM THERMAL ENERGY STORAGE BRANDEIS UNIVERSITY (US) 2021-08-12 WO disclosed
WO-2021122175-A1 REVERSIBLE, OPTICALLY SWITCHABLE ADHESIVES BASED ON ARYLAZO-3,5-DIMETHYLISOXAZOLE DERIVATIVES Westfälische Wilhelms-Universität Münster (DE) 2021-06-24 WO disclosed
US-20170114044-A1 PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS TAKEDA PHARMACEUTICALS CO (JP) 2017-04-27 US disclosed
US-20170114044-A1 PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS TAKEDA PHARMACEUTICALS CO (JP) 2017-04-27 US disclosed
US-20170114044-A1 PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS TAKEDA PHARMACEUTICALS CO (JP) 2017-04-27 US disclosed
US-9550756-B2 Pyridazinone compounds as phosphodiesterase inhibitors and methods of treating disorders TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-01-24 US disclosed
US-20100197651-A1 Pyridazinone compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-05 US disclosed
US-20100197651-A1 Pyridazinone compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-05 US disclosed
US-20050272709-A1 Immugenic compositions and diagnostic and therapeutic uses thereof DERMIRA (CANADA), INC. 2005-12-08 US disclosed
EP-1450791-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS Kinetek Pharmaceuticals, Inc. (CA) 2004-09-01 EP disclosed
WO-2003045379-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS KINETEK PHARMACEUTICALS, INC. (CA) 2003-06-05 WO disclosed
US-6169087-B1 Modulators of protein tyrosine phosphatases (PTPases) NOVO NORDISK A/S (DK) 2001-01-02 US disclosed
EP-1017697-A1 MODULES OF PROTEIN TYROSINE PHOSPHATASES (PTPases) NOVO NORDISK A/S (DK) 2000-07-12 EP disclosed
WO-1999015529-A1 MODULES OF PROTEIN TYROSINE PHOSPHATASES (PTPases) NOVO NORDISK A/S (DK) 1999-04-01 WO disclosed
US-4006132-A 1'-Formyl-1'-halobenzeneazomethane compounds having herbicidal activity THE UPJOHN COMPANY (US) 1977-02-01 US disclosed
US-3932662-A ANTHELMINTICS, PYRUVOYL CHLORIDE PHENYLHYDRAZONES THE UPJOHN COMPANY (US) 1976-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230053197-A1 ARYLAZO-HETEROARYL COMPOUNDS AND THEIR USE FOR LONG-TERM THERMAL ENERGY STORAGE NQO1, CBR1, AHR MAPT 4221/4885RAB9A 883/4885SMN1; SMN2 1645/4885
US-12497368-B2 Arylazo-heteroaryl compounds and their use for long-term thermal energy storage NQO1, RECQL, AHR MAPT 2275/4885RAB9A 619/4885SMN1; SMN2 1735/4885
US-20050272709-A1 Immugenic compositions and diagnostic and therapeutic uses thereof MKI67, CDK4, CCNC MAPT 4000/4885RAB9A 3555/4885SMN1; SMN2 2243/4885
US-20170114044-A1 PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS PDE3A, PDE5A, PDE3B MAPT 4321/4885RAB9A 904/4885SMN1; SMN2 3025/4885
US-20100197651-A1 Pyridazinone compounds PDE3A, PDE5A, PDE3B MAPT 4144/4885RAB9A 495/4885SMN1; SMN2 3277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.